Member Info for PM2022

Yes but you sold most of your stock. Fact is shareholders voted to keep them on so we move on rather than constantly attacking the stock and BOD.

No removing exclusivity is not the solution and personally I see it as an agenda to buy cheaper.

If you see offense then I apologise to you but honestly I see no personal attack. I said how I see it but if you are upset then accept my apology as no offense intended.. Not interested in petty childish arguments and no I am not attacking you. As I said I say how I see it good or bad.

I stated what I stated here plus other comments relating to pulling 201 and so on. I do not agree it is in the best interests of shareholders and I have told you that on numerous occasions. You have sold down so yes it is your choice but as I said it does impact share price and sentiment. I have nothing personal against you. I think you're a nice guy. Not sure where you see offense but I say how I see it and think nothing more.

Focus on the stock and not on people. You never got things your way so clearly you are frustrated but don't come here taking it out on others.

Nick cool you made your point. As you were such a large holder with many millions you selling down with market conditions does have an impact on sentiment and share price. It is your choice but nothing wrong with the truth so the low SP is in part down to the opinions of some individuals which can be wrong. Therefore saying I was wrong holds no weight.

Anyway if you can prove why the SP should be 7p which Adam and BOD believe to be undervalued then why not step on the BOD yourself and show how it is done.

Focus on moving forward and stop moaning.

What we missed in the past are good updates at times when news should have come. I am sure Adam will go over all the compounds and see when a good value adding RNS can land. Updates for 301 and CLX can come soon plus content in the RNS is important and how it is presented. He can make sure the Lab business is value adding making sure we don't burn too much cash without generating revenue and eventually profit first. Once that is done institutional investors will come in. It is all set up well now.

BOD will still make the calls but at least he can discuss issues and ensure the correct decisions are being made. He can make suggestions when needed. I feel this was all that was needed. He does not have the time to be a CEO so this type of role is perfect for everyone at the moment. If he later decides to join the BOD as well then great but happy with the current progress.

I ignore individuals who have sold and have agendas but I have more faith that the news flow will make the real impact now. Fully behind Valirx now. Everyone knows the potential here is not just about 201 especially given our current MC of only 7 million .

I back the decision to vote all BOD in if Adam had some influence going inside as it is the best outcome and the least disruptive. We can now build fast and build strong momentum.

Completely different position than before and now gets to see everything. Before he was outside and because he could not see anything felt it was pointless.

He runs a lab business and has clients and knows the business. Also owns 8% so all decisions will be in the best interests of shareholders and value adding. Expecting decent revenue to come through in the next 3 months.

It will not take much to double/triple from here. Adam was also big on an early deal so hopefully in the next 6-12 months CLX could come into play big time.

Strong buy.

Best news of the last 3 years. Brilliant.

Great decisions ahead. Knows the business and has a business mind.

Full confidence now.

A recent exchange with Suzy confirmed they will seek very significant revenue before even considering adding additional lab staff. No more buying assets here. Therefore no more costs on top of what we have.

Cash until the middle of 2024. It is very easy to get the SP up to 15 p at least even without 201/301 which I think we will get news on in the next 6 months. If we don't Stella can buy 500k/1 million shares before placing SP goes to 12 p with some other buyers jumping in. Get some lab contracts out and we are at least 15-20 p range with some compounds coming in. Markets cannot get any worse so we should see an improvement in the AIM market at some point in the next 12 months. Failing that we have Adam who could join BOD to bring confidence. Plenty of options available.

They gain nothing from a single digit placing. Don't forget Suzy and Kevin have about 400/500 K shares and any more they purchase will turn to dust unless they bring confidence and take SP within the time frame. Plenty of value here just have confidence and be fearless.

So Metom is selling a few. No problem. Once he sells we will go up to 10-15 p range. An easy trade. I purchased a few today and yesterday.

We will get significant lab contracts coming soon that will show decent revenue and hopefully profit coming through. No more buying assets for now at these prices.

We have cash until the middle of 2024. Several options available to take SP up.

New compounds coming through, 201 still on, news on 301, lab contracts in the coming months enough cash until middle of 2024. I back BOD to buy in soon as well. Any one of these factors could be worth 2-5 times our market cap in the short term.

7 million market cap with CLX which has been going on for the last 18 months. Remember SAR got to 300 million based on one preclinical compound. The revenue and profit will bring in II which itself will increase the SP massively.

Always some risk but any hint of success anywhere and we could go up 5/10 times our MC fairly quickly.

If it goes down 5-10% for a few days or weeks then no problem but more likely to go up. In the medium term I still think we can 10-20 bag fairly easily.

Those that think we will have a placing just remember they only requested 20 million shares. The SP will need to go up from the current SP significantly to raise anything decent and they have plenty of time. Decent buy at the current prices.

The first half of the year has been one of steady progress for the Company's two main investments. As previously stated, it is the Board intention to establish up to date valuations for these two investments during 2023. A formal sales process has been initiated by the Board for its stake in SatoshiPay which is expected to complete by the end of 2023. There is no guarantee this will lead to an acceptable offer or that the Board will accept an offer. Below we provide the following portfolio company highlights, inclusive of updates, for the six-month period ended 31 March 2023 and any subsequent developments.

Porky, Stella said that she never invested because of comments made on BB against the BOD and the company causing instability. Only one person here does that and that is you. That in turn is likely costing Stella her job.

Maybe you are the real problem. TIme you found something better to do in life.

The more you ramp Stella in the more likely she is to go as by now everyone just does the opposite to what you say.

I think they will buy after the AGM as that makes sense as they need to be sure who stays. They know they have to get the SP to 30/40p to activate those options by next year and I think they will. A decent amount for both Suzy and Kevin.

I think all these extras with the Lab will help get some big contracts and significant revenues this year which hopefully will attract ii's. It all helps. PYC collaboration, Imagen Therapeutics and now this. We should see significant revenues contracts coming through in the coming weeks.

New compounds are also due soon, 201 deal is still likely to be completed according to BOD and CLX updates so at least it is onwards and upwards from here. All for 8 million but surely this will rerate to at least 30 million this year.

About OncoBone

OncoBone offers scientific expertise to pharmaceutical and biotech industry and their service providers globally. OncoBone representatives have a long history of working in CRO business and a large global network of high-quality CRO partners. OncoBone utilizes this extensive experience to guide pharma/biotech companies in need of CRO services to work with the best fit CRO partners. OncoBone can assist its pharma/biotech clients in their preclinical-stage programs through its Virtual CRO concept, where OncoBone subcontracts the work to its CRO partners and manages the projects internally.

The drop on Friday was not justified. When a new compound is taken into evaluation it is worthless and SP does not go up so not sure SP should go down 20% when it fails.

With CLX worth at least 20p at the moment, 201 still on and Lab nicely set up to bring some significant revenue in fast then the future is looking bright. We still have Barcelona in evaluation and some more will be coming soon including and likely 301 and suddenly we will seem like a company worth at least £30 million. Throw in 201 over the coming months and the future is bright.

A great buy at 8p. Surely with all this and cash until mid/late 2024 we should be worth at least 20/25p at the moment.

Elis,

Yes that is partly why we are where we are. It will change and we will be back to normal SP around 20 p when it happens in the coming weeks/months. As you know nothing lasts forever so now is the time.

Later must go.

Elis,

You know asset value is at least 30 million if CLX is worth 20 p.

I believe a takeover bid must be imminent at this SP. If it comes everyone gets locked out.

201 hits you also get locked out. Market makers will take this straight to 25 p. Don't get greedy now is the time.

Elis,

Time to buy is now IMO but patience required. Remember 201 can come at any moment. We had 4/5 RNS over the last week. I lost count.

The next one could be the deal.

People don't spend the time you do on LSE. It's called multitasking. It matters not.

No need to spend more than 5 seconds typing.

WCB AKA Lockdown,

I am not one to spend my time trolling others. Go out and enjoy the weather since you are a retired old man.

Surprising you troll at your age. Easy to do behind the screen. Come to London and do it face to face and then we can see how big a man you are.

Spend your time more wisely since you are not invested here.

I have added Kevin to my list as well. The reason is simply they would have had an idea of outcomes but refused to increase confidence by inviting Adam but clearly they refused to do so. Stella has not purchased and this has had a negative outlook on the stock.

If they were acting in the best interests of the company and shareholders they would have taken steps to build confidence and looked at ways to achieve this.

They are happy for the SP to tank as long as they keep roles. We cannot afford any more mistakes so a shareholder needs to be on the board.